Literature DB >> 1117505

An evaluation of lymphangiography in staging carcinoma of the prostate.

J C Cerny, R Farah, R Rian, M L Weckstein.   

Abstract

Pedal lymphangiography was done on 38 patients with stages O, A and B carcinoma of the prostate. The lymphangiograms were positive in 19 cases and negative in 19. Of 18 patients who underwent lymphadenectomy (9 with positive and 9 with negative studies) operative findings confirmed the lymphangiogram in 15 (83 per cent). In the 6 patients with osseous metastases and/or enzyme elevation, the lymphangiogram was positive. Furthermore, 13 patients with positive lymphangiograms had negative osseous and enzyme survey, emphasizing that nodal involvement may be the earliest finding in disseminated carcinoma of the prostate. The value of lymphangiography in staging carcinoma of the prostate prior to radical prostatectomy or irradiation seems well established.

Entities:  

Mesh:

Year:  1975        PMID: 1117505     DOI: 10.1016/s0022-5347(17)59483-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Urology: clinicopathologic features of unsuspected lymph node metastases in prostatic carcinoma.

Authors:  S L Saltzstein; A P McLaughlin
Journal:  West J Med       Date:  1977-01

2.  The lymphatics of the prostate gland and their role in the spread of prostatic carcinoma.

Authors:  P Shridhar
Journal:  Ann R Coll Surg Engl       Date:  1979-03       Impact factor: 1.891

Review 3.  Radiologic imaging modalities, including magnetic resonance, for evaluating lymph nodes.

Authors:  G C Dooms; H Hricak
Journal:  West J Med       Date:  1986-01

4.  RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.

Authors:  Colleen A F Lawton; Jeff Michalski; Issam El-Naqa; Mark K Buyyounouski; W Robert Lee; Cynthia Menard; Elizabeth O'Meara; Seth A Rosenthal; Mark Ritter; Michael Seider
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-22       Impact factor: 7.038

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.